TRACON Pharmaceuticals (TCON) and Its Peers Financial Review

TRACON Pharmaceuticals (NASDAQ: TCON) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare TRACON Pharmaceuticals to related companies based on the strength of its analyst recommendations, risk, institutional ownership, valuation, earnings, dividends and profitability.

Earnings & Valuation

This table compares TRACON Pharmaceuticals and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
TRACON Pharmaceuticals $3.45 million -$27.00 million -2.46
TRACON Pharmaceuticals Competitors $284.49 million $34.10 million 77.15

TRACON Pharmaceuticals’ rivals have higher revenue and earnings than TRACON Pharmaceuticals. TRACON Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for TRACON Pharmaceuticals and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TRACON Pharmaceuticals 0 1 1 0 2.50
TRACON Pharmaceuticals Competitors 882 3256 11745 235 2.70

TRACON Pharmaceuticals presently has a consensus price target of $6.00, suggesting a potential upside of 100.00%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.63%. Given TRACON Pharmaceuticals’ higher possible upside, research analysts clearly believe TRACON Pharmaceuticals is more favorable than its rivals.


This table compares TRACON Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
TRACON Pharmaceuticals -201.21% -83.43% -49.01%
TRACON Pharmaceuticals Competitors -5,310.77% -218.27% -39.48%

Insider and Institutional Ownership

34.1% of TRACON Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.1% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 5.3% of TRACON Pharmaceuticals shares are owned by insiders. Comparatively, 17.3% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.


TRACON Pharmaceuticals rivals beat TRACON Pharmaceuticals on 9 of the 12 factors compared.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company’s lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.

Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit